Cantor Fitzgerald Upgrades Monopar Therapeutics (NASDAQ:MNPR) to Overweight

by · The Markets Daily

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) was upgraded by equities researchers at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a research report issued on Thursday, Marketbeat.com reports. The firm presently has a $119.00 target price on the stock. Cantor Fitzgerald‘s target price points to a potential upside of 67.90% from the stock’s current price.

Several other analysts also recently weighed in on MNPR. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. HC Wainwright increased their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Barclays reissued an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.78.

Check Out Our Latest Analysis on MNPR

Monopar Therapeutics Stock Down 1.2%

Monopar Therapeutics stock traded down $0.85 during midday trading on Thursday, reaching $70.88. The company’s stock had a trading volume of 189,458 shares, compared to its average volume of 202,720. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82. The company has a market cap of $475.71 million, a P/E ratio of -32.72 and a beta of 1.62. The business has a 50-day simple moving average of $84.40 and a 200-day simple moving average of $77.39.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.10. As a group, equities analysts forecast that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, CEO Chandler Robinson sold 29,056 shares of the stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $68.35, for a total value of $214,755.70. Following the completion of the sale, the director directly owned 5,373 shares of the company’s stock, valued at approximately $367,244.55. This trade represents a 36.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock valued at $4,527,913 in the last three months. 9.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. grew its stake in shares of Monopar Therapeutics by 18.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock worth $132,000 after purchasing an additional 262 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at about $250,000. Sei Investments Co. boosted its holdings in Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares in the last quarter. Bank of America Corp DE boosted its holdings in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in Monopar Therapeutics during the first quarter worth about $3,458,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

See Also